About RSV

RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the United States.

Recent estimates suggests that approximately 200,000 hospitalizations in the U.S. and EU occur each year in children under the age of two, and approximately 170,000 hospitalization in these regions occur each year in adults age 65 and older. 

Respiratory Syncytial Virus (RSV)


Respiratory Syncytial Virus (RSV) is a virus that infects the lungs and represents a serious unmet medical need in infants and children, as well as immune-compromised individuals and the elderly. RSV is the most common cause of bronchiolitis and pneumonia in children under the age of one. In one large U.S.-based study, RSV infection in children was associated with 20% of hospitalizations, 18% of emergency department visits, and 15% of pediatric office visits for acute respiratory infections in the November-April time frame. Though a prophylactic monoclonal antibody-based treatment is available for those considered at high risk for RSV infection, this study (palivizumab) found that most young children affected by RSV infection were previously healthy, and thus would not normally be considered for prophylaxis. There is currently no safe and effective treatment available for treating RSV infection.

Enanta has selected EDP-938, a potent non-fusion inhibitor of both RSV-A and RSV-B activity, as its first development candidate for RSV.  Top-line results of a Phase 2 challenge study of EDP-938 were announced in June 2019 showing EDP-938 achieved highly statistically significant (p<0.001) reduction in viral load and resolution of clinical symptoms compared to placebo. Preclinical data also demonstrated a rapid reduction in viral load, below the limits of detection (LOD), in animals treated with EDP-938.

For an overview of our research, including our licensed products, please see Our Pipeline.